| Haemophilia treatment centres and national patient registries
Of the 37 respondent countries, 23 stated that they have a recognized haemophilia treatment centre (HTC) with responsibility for areas such as coordination or a registry, while 14 countries do not.
Of the 37 respondent countries, 16 stated that they have a system of classification for HTCs, while 21 countries do not. Of these 16 countries, 11 countries have a recognized HTC with coordination or registry responsibility, namely Armenia, Belgium, Bulgaria, Czech Republic, Georgia, Ireland, Norway, Poland, Slovakia, Sweden and the UK.
A total of 29 countries have a national patient registry, and eight countries do not. The countries that do not yet have a registry are Estonia, Kyrgyzstan, Lithuania, Macedonia, the Netherlands, Portugal, Sweden and Ukraine. In terms of the management of the registry, in 13 countries, the haemophilia centre is involved, in another 13 countries, the haemophilia patient organization is involved, in seven countries, the government is involved, in four countries, the national organization (NHC or coordinating group) is involved, in one country a teaching hospital is involved and in 11 countries other institutions are involved. In relation to national decision-making on haemophilia care, 32 countries stated that the Health Ministry plays a significant role, of which eight countries also stated that the government plays a significant role (Albania, Armenia, Hungary, Italy, Norway, Russia, Sweden and Switzerland) and four countries also stated that the Social Affairs Ministry plays a significant role (Finland, Germany, Romania and Russia). A total of five countries stated that patients play a significant role (Macedonia, Romania, Slovakia, Slovenia and the UK), whereas 20 countries stated that the haemophilia patient organizations play a significant role, and 27 countries stated that clinicians play a significant role. A total of 16 countries reported shared decision-making in national haemophilia care between patients/patient organizations, clinicians and government bodies (Armenia, Austria, Denmark, Germany, Ireland, Macedonia, the Netherlands, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Sweden, Turkey and the UK).
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In relation to choice of haemophilia treatment products, 27 coun- 
| Home treatment
It is widely accepted that home treatment and home delivery should be available in each country to facilitate immediate and effective treatment. Home treatment is available in 32 of the 37 countries (Table S3) 
| Prophylaxis
It is commonly accepted that prophylaxis is the optimal treatment strategy for patients with severe haemophilia and absence of its availability is associated with long-term joint destruction and high annualized bleed rates. The reported proportions of patients with access to prophylactic regimens are based on the severe patient population The EHC survey found that in 17 countries, all PWH reportedly have access to prophylaxis. In nine countries, some PWH have access and in seven countries only children have access to prophylaxis (Table S3 ).
In total, children have access to prophylaxis in 30 of 37 countries (Table S3) . In 26 countries, 76%-100% of children have access, in two countries (Romania and Serbia) 51%-75% and in another two (Azerbaijan and Ukraine) 26%-50% of children have access. Three countries (Denmark, Italy and the Netherlands) did not report these data.
Regarding adults, in seven countries, 76%-100% of adults have access to prophylaxis (Belgium, Ireland, Latvia, the Netherlands, Norway, Slovenia and Sweden), whereas in five countries, 51%-75% of adults have access (Austria, Finland, Germany, Poland and UK). In nine countries, 26%-50% of adults have access and in eight countries, 1%-25% of adults have access to prophylaxis. Denmark and Italy did not report these data.
In Albania, Armenia, Georgia and Kyrgyzstan, neither children nor adults have access to prophylaxis and in these countries, home treatment is also not available. In addition to these countries, adults in Romania and Ukraine have no access.
| Immune tolerance induction

Seven countries reported that immune tolerance induction (ITI)
is never available to PWH who have inhibitors (Albania, Armenia, Kyrgyzstan, Macedonia, Montenegro, Romania and Ukraine). In 15 countries, ITI is available to all PWH with inhibitors, in four countries it is available to 76%-100% (Austria, Hungary, Poland and Sweden), in two countries it is available to 51%-75% (Portugal and Russia) and in seven countries it is available to 1%-25% (Azerbaijan, Bulgaria, Estonia, Georgia, Lithuania, Serbia and Turkey) (Table S3 ). Italy and Latvia did not report these data.
T A B L E 1 Changes in access to home treatment, immune tolerance induction (ITI) and prophylaxis in both children and adults in responding countries between 2012 and 2015
Home treatment ITI
Prophylaxis in children
Prophylaxis in adults
↑ increase in access; ↓ decrease in access -countries with no change were not included in the table.
| Specialist care
To assess the availability of comprehensive care, countries were asked the degree of access to a number of specialty services, including emergency medicine and acute surgery, paediatrics, infectious diseases, hepatology, rheumatology, orthopaedics, physiotherapy, dentistry, obstetrics and gynaecology, genetics, social and psychological support, pain management, general surgery and urology ( (Table S4) .
| Treatment of haemophilia
In terms of access to treatments, 19 countries reported that both plasma-derived and recombinant factor concentrates are always available. A total of 29 countries stated that recombinant factor concentrates are always available; of those, 10 countries reported that they rarely have plasma-derived factor concentrates available. A total of 26 countries state that plasma-derived factor concentrates are always available; of those, five countries stated that they rarely have recombinant factor concentrates available and one country (Montenegro) stated that it never has access to recombinant factor concentrates. Estonia, Kyrgyzstan and Ukraine reported that plasma and cryoprecipitate are always used. In six countries, cryoprecipitate is reportedly used infrequently (Albania, Azerbaijan, Georgia, Romania, Russia and Serbia) and in 10 countries, plasma is reportedly used infrequently (Tables 3 and S5 ).
| Treatment of von Willebrand's Disease
A total of 30 countries reported that they always have plasma-derived factor concentrates available for the treatment of VWD, whereas four countries (Albania, Kyrgyzstan, Montenegro and the Netherlands) reported rarely having access to plasma-derived factor concentrates, and Latvia and Macedonia reported never using plasma-derived factor concentrates to treat VWD. With regard to desmopressin (DDAVP), 21 countries reported always having DDAVP available for the treatment of VWD, whereas nine countries reported rarely having DDAVP available and four countries reported never having DDAVP available for treatment (Armenia, Czech Republic, Macedonia and Russia; Table 3 and S5).
| Per capita factor use
Of 37 respondent countries, 27 reported factor VIII and 25 reported factor IX use per capita for 2014 (Table S3) (Table S6 and Figure S6 ).
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T A B L E 2
| Cross-border health care
The EHC asked its national patient organizations whether, to the 
| Ageing
Regarding preparedness for supporting an ageing haemophilia population, of 37 respondent countries, six countries reported being aware of specific clinical services for ageing PWH (Belgium, Greece, the Netherlands, Serbia, Sweden, Switzerland); eight countries reported having guidelines for managing cardiovascular disease in older PWH (Austria, Belgium, Georgia, Israel, the Netherlands, Norway, Spain, UK); 16 countries reported being aware of educational programmes for patients or physicians on the healthcare issues of older PWH; and 21 countries reported that their patients or centres had raised concerns about the provision of care for older adults with haemophilia.
| DISCUSSION
The 2015 survey results show a general increase in per capita FVIII use in the past 3 years, ranging between three per cent and 107 per exposed to infection with, or mortality from, HIV. In the next survey, we will look to assess the average use per patient per year with severe countries. This is a matter of concern as these bodies are ideal vehicles for coordination of haemophilia care. A further recommendation was that the minimum FVIII use per capita in any country should be 3 IU per capita. In 2013, 13 countries reported per capita FVIII use below 3 IU per capita. In this survey, eight countries reported per capita use below this figure but no data are available for ten countries. Following this survey, further EDQM recommendations were agreed in 2016, which should be published in the near future. Our future surveys will track the progress in implementing these new recommendations.
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